about
Low autochtonous urban malaria in Antananarivo (Madagascar)Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malariaAfrican apes as reservoirs of Plasmodium falciparum and the origin and diversification of the Laverania subgenusPlants traditionally prescribed to treat tazo (malaria) in the eastern region of MadagascarGenomic analysis of local variation and recent evolution in Plasmodium vivax.Post-deployment effectiveness of malaria control interventions on Plasmodium infections in Madagascar: a comprehensive phase IV assessment.Monitoring parasite diversity for malaria elimination in sub-Saharan AfricaMultiple host-switching of Haemosporidia parasites in batsA Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms.Do ethnobotanical and laboratory data predict clinical safety and efficacy of anti-malarial plants?Nationwide evaluation of malaria infections, morbidity, mortality, and coverage of malaria control interventions in Madagascar.Assessment of the efficacy of antimalarial drugs recommended by the National Malaria Control Programme in Madagascar: up-dated baseline data from randomized and multi-site clinical trials.Anthropophilic mosquitoes and malaria transmission in the eastern foothills of the central highlands of Madagascar.Modeling the burden of poultry disease on the rural poor in Madagascar.Phylogeny, evolutionary trends and classification of the Spathelia-Ptaeroxylon clade: morphological and molecular insights.The origins of African Plasmodium vivax; insights from mitochondrial genome sequencingFirst evidence of pfcrt mutant Plasmodium falciparum in Madagascar.Spontaneous mutations in the Plasmodium falciparum sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase (PfATP6) gene among geographically widespread parasite populations unexposed to artemisinin-based combination therapies.Invasion of Africa by a single pfcrt allele of South East Asian typeUse of pre-packaged chloroquine for the home management of presumed malaria in Malagasy children.Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax.Longitudinal survey of malaria morbidity over 10 years in Saharevo (Madagascar): further lessons for strengthening malaria control.Diversity, Host Specialization, and Geographic Structure of Filarial Nematodes Infecting Malagasy Bats"Tazomoka Is Not a Problem". Local Perspectives on Malaria, Fever Case Management and Bed Net Use in Madagascar.World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.Pooled Amplicon Deep Sequencing of Candidate Plasmodium falciparum Transmission-Blocking Vaccine Antigens.Multiple causes of an unexpected malaria outbreak in a high-transmission area in Madagascar.Effectiveness of malaria control interventions in Madagascar: a nationwide case-control survey.Atelier paludisme: an international malaria training course held in Madagascar.K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa.Activation of minority-variant Plasmodium vivax hypnozoites following artesunate + amodiaquine treatment in a 23-year old man with relapsing malaria in Antananarivo, Madagascar.Nonradioactive heteroduplex tracking assay for the detection of minority-variant chloroquine-resistant Plasmodium falciparum in MadagascarLessons learnt from the six decades of chloroquine use (1945-2005) to control malaria in Madagascar.Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysisEntomological and parasitological impacts of indoor residual spraying with DDT, alphacypermethrin and deltamethrin in the western foothill area of Madagascar.Analysing trends and forecasting malaria epidemics in Madagascar using a sentinel surveillance network: a web-based applicationPitfalls in new artemisinin-containing antimalarial drug development.[French language training course: malaria workshop organized by Institut Pasteur de Madagascar]In-vitro sensitivity of Plasmodium falciparum to chloroquine, halofantrine, mefloquine and quinine in Madagascar.Susceptibility of Plasmodium falciparum to the drugs used to treat severe malaria (quinine) and to prevent malaria (mefloquine, cycloguanil) in Comoros Union and Madagascar.
P50
Q21033513-9224244f-4ad5-28ac-3d53-6d31026ee525Q21034136-66f3877b-4b94-b52c-1f22-1c0159401ab3Q24630492-3B15965A-FE61-4372-868A-75D7DE50AADFQ24795235-595DDC2E-A935-4BE2-AF2A-DB2DF9759413Q27149930-27227493-C1FD-4EFD-A016-8CBDA5D4A743Q27304582-88F73F42-FF21-4413-B789-9115D09DBDB3Q28610494-0D260C1E-DE58-4AB5-8D5A-CF3BAAC4EED3Q28755879-6126480A-05B6-4FD4-AA37-93DBFF18542EQ30379780-B785BFC0-11BF-470D-BBBC-F536C446EA58Q30396380-1B6E5C1D-5A44-45CC-865E-C14C8AFBAF5EQ30614231-9C5CB047-A5F0-4868-81D8-76873B0FA667Q31151729-22E60590-D38D-4D2C-B0F7-D960672C4136Q33678392-9EB4CEBE-D55F-4964-A833-1B329E9FD8D1Q33718276-097C3033-5DE5-472E-B17C-0175D94D9EF8Q33910811-752B87E3-2C5C-4D30-9CA9-A837C9E23187Q34110751-D4E83905-2909-49B8-A1EF-6E362F06BDE2Q34151385-CDCFEC43-3651-4259-96F2-DA1E113B2E75Q34483513-9203791A-9117-4837-A882-753FFC5553E3Q34602866-B2024B60-A14B-49B6-8C88-4658A63596DFQ35069313-89424C4E-3FA3-4307-9FEE-32C198DD066CQ35088997-063CDB68-997A-492F-BBE3-15826AACD621Q35575322-8E9C913D-9683-46D0-BB98-D9801B50D67CQ35890179-9F1649DE-0233-4621-82D6-241042B25801Q35946224-028788F6-A1B6-4282-BB0E-DAF5D166A5DFQ36054710-76311EC2-AFD7-4CBF-8CEE-90ED33938F23Q36455757-CF08B9F2-6E5A-4147-AF4B-A4A0ADB4509BQ36538476-0F3BE233-DE6A-4371-8CDD-AFEC92BEA488Q36574993-E0706689-9E4E-4511-8330-C78834EEAB38Q36671907-8EA31BBC-1E0E-4FC9-8F88-24DBD91BD0BBQ36786733-82035803-452A-4F44-8625-B70C6BB0A13EQ36901081-C2A20549-5981-482E-AF04-43B71E9878FAQ37148927-B6F5DC6A-D71D-4BEF-88C7-0B0244B2186FQ37309766-3BCB0205-339B-43CF-A94E-351EEB9BB29EQ37350167-1625D34B-C83F-4BEE-B9DC-C1B293E4CA42Q37531847-C54AFFBF-D180-485B-9823-3E64D03EAD89Q37640560-424357C1-9E47-4038-A0E3-D7091F7D17C1Q37804584-6A9CFDC1-4578-4E12-B832-3581395B2D4EQ38478088-DFABA994-0897-41C4-8841-D8688ACB3D1CQ39644266-D182DE43-3970-4463-81F9-79E1D3697ABBQ39676504-690984FF-C99F-419D-9C00-E00D0C9C6A03
P50
description
farmacoloog
@nl
hulumtuese
@sq
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Milijaona Randrianarivelojosia
@ast
Milijaona Randrianarivelojosia
@br
Milijaona Randrianarivelojosia
@co
Milijaona Randrianarivelojosia
@da
Milijaona Randrianarivelojosia
@de
Milijaona Randrianarivelojosia
@en
Milijaona Randrianarivelojosia
@es
Milijaona Randrianarivelojosia
@fr
Milijaona Randrianarivelojosia
@id
Milijaona Randrianarivelojosia
@it
type
label
Milijaona Randrianarivelojosia
@ast
Milijaona Randrianarivelojosia
@br
Milijaona Randrianarivelojosia
@co
Milijaona Randrianarivelojosia
@da
Milijaona Randrianarivelojosia
@de
Milijaona Randrianarivelojosia
@en
Milijaona Randrianarivelojosia
@es
Milijaona Randrianarivelojosia
@fr
Milijaona Randrianarivelojosia
@id
Milijaona Randrianarivelojosia
@it
altLabel
Milijaona
@en
prefLabel
Milijaona Randrianarivelojosia
@ast
Milijaona Randrianarivelojosia
@br
Milijaona Randrianarivelojosia
@co
Milijaona Randrianarivelojosia
@da
Milijaona Randrianarivelojosia
@de
Milijaona Randrianarivelojosia
@en
Milijaona Randrianarivelojosia
@es
Milijaona Randrianarivelojosia
@fr
Milijaona Randrianarivelojosia
@id
Milijaona Randrianarivelojosia
@it
P108
P269
P106
P1412
P21
P214
7294148390848110830006
P269
P31
P496
0000-0003-2767-0349
P7859
viaf-7294148390848110830006